Posted by Michael Wonder on 21 Mar 2024
GSK announces cap of $35 per month on US patient out of pocket costs for its entire portfolio of asthma and COPD inhalers
20 March 2024 - Announcement builds on GSK’s decades-long commitment to making products accessible to those who need them.
GSK today announced it will cap out of pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease medicines, the most prescribed portfolio of inhalers in the US.
